Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634225 | 0.95 | ALDH1A1 (0.56) | ALDH1A1HPGDERCC5FEN1HSD17B3 | |
| SCHEMBL633475 | 0.93 | ALDH1A1 (0.55) | ALDH1A1HPGDERCC5FEN1HSD17B3 | |
| SCHEMBL634326 | 0.93 | ALDH1A1 (0.55) | ALDH1A1HPGDERCC5FEN1HSD17B3 | |
| SCHEMBL634434 | 0.89 | ERCC5 (0.57) | ALDH1A1HPGDERCC5FEN1HSD17B3 | |
| SCHEMBL10482996 | 0.87 | HSD17B3 (0.60) | ALDH1A1HSD17B3MAPTHTR7HTT | |
| SCHEMBL11703262 | 0.84 | ERCC5 (0.56) | ALDH1A1HPGDERCC5FEN1MAPT | |
| SCHEMBL19757423 | 0.84 | HSD17B3 (0.55) | ALDH1A1HPGDHSD17B3MAPTHTT | |
| SCHEMBL10792681 | 0.83 | PARP1 (0.55) | ALDH1A1HPGDERCC5FEN1MAPT | |
| SCHEMBL5660410 | 0.83 | ERCC5 (0.54) | ALDH1A1HPGDERCC5FEN1MAPT | |
| SCHEMBL17410088 | 0.83 | ERCC5 (0.54) | ALDH1A1HPGDERCC5FEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9683003-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-2419400-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121022-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-2099761-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 521/4885HPGD 2548/4885ERCC5 3254/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 521/4885HPGD 2548/4885ERCC5 3254/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 521/4885HPGD 2548/4885ERCC5 3254/4885 |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | ALDH1A1 1512/4885HPGD 3468/4885ERCC5 1267/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | ALDH1A1 1512/4885HPGD 3468/4885ERCC5 1267/4885 |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | ALDH1A1 1512/4885HPGD 3468/4885ERCC5 1267/4885 |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | ALDH1A1 2406/4885HPGD 1607/4885ERCC5 4023/4885 |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | ALDH1A1 1512/4885HPGD 3468/4885ERCC5 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.